The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Kidney Cancer (Renal Cell Carcinoma) — Diagnosis and Modern Treatment

Contemporary management of renal cell carcinoma (RCC), including incidental detection trends, robotic partial nephrectomy, immune checkpoint inhibitor combinations, and risk-stratified surveillance protocols.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Onkoloji department. Book Appointment →

What is Kidney Cancer (Renal Cell Carcinoma) — Diagnosis and Modern Treatment?

Renal cell carcinoma (RCC) arises from the renal tubular epithelium and encompasses several histologic subtypes with distinct molecular profiles. Clear cell RCC (75-80%) is characterized by VHL gene inactivation leading to HIF stabilization and pseudohypoxic signaling. Papillary RCC (10-15%) includes type 1 (associated with MET mutations) and type 2 (heterogeneous, including CDC fumarate hydratase-deficient and TFE3 translocation variants).

Other RCC subtypes include chromophobe RCC (5%, generally indolent with TP53 alterations), collecting duct carcinoma (rare, aggressive), renal medullary carcinoma (associated with sickle cell trait), and translocation RCC (TFE3/TFEB family, more common in young patients). Hereditary syndromes contribute to 5-8% of cases including von Hippel-Lindau, hereditary papillary RCC, Birt-Hogg-Dubé, hereditary leiomyomatosis-RCC, and tuberous sclerosis complex.

Approximately 60% of RCCs are now detected incidentally on imaging performed for other reasons. Diagnostic evaluation includes multiphasic contrast-enhanced CT or MRI characterizing solid renal masses, with the classic triad of flank pain, hematuria, and palpable mass present in only 6-10% of cases at presentation. Staging utilizes TNM and integrates with risk stratification systems (IMDC criteria for metastatic disease) to guide treatment selection across the spectrum from active surveillance to combination immunotherapy.

Symptoms

Hematuria (gross or microscopic)
Flank pain and abdominal mass (classic triad, late finding)
Unexplained weight loss and constitutional symptoms
New onset varicocele (especially right-sided, suggests venous obstruction)
Anemia, hypercalcemia, or polycythemia (paraneoplastic)
Many cases are asymptomatic, detected incidentally on imaging
Bone pain or pathologic fracture in metastatic disease

Risk Factors

Tobacco smoking (relative risk 1.5-2.5)
Obesity, particularly in women
Chronic hypertension
Acquired cystic kidney disease in dialysis patients
Hereditary syndromes (VHL, HPRC, BHD, HLRCC, TSC)
Long-term analgesic abuse (phenacetin)
Occupational exposure to trichloroethylene

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Visible blood in urine without obvious cause
  • Persistent flank or back pain
  • Palpable abdominal mass
  • Unexplained weight loss with anemia
  • New onset varicocele particularly right-sided
  • Family history of hereditary kidney cancer syndromes
  • Incidental renal mass detected on imaging requiring characterization

Treatment Methods

01
Active surveillance for small renal masses (<2 cm) in elderly or comorbid patients
02
Robotic or laparoscopic partial nephrectomy (nephron-sparing standard)
03
Radical nephrectomy for large or central tumors not amenable to partial
04
Percutaneous thermal ablation (cryoablation, RFA) for select small masses
05
Cytoreductive nephrectomy in select metastatic patients
06
First-line systemic therapy: ipilimumab-nivolumab, pembrolizumab-axitinib, or pembrolizumab-lenvatinib
07
Adjuvant pembrolizumab for high-risk resected disease (KEYNOTE-564)

Which Department to Visit?

You can visit our Onkoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Onkoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.